{"id":"ziprasidone-injection","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Somnolence"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Dizziness"},{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"QT prolongation"},{"rate":"5-10","effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ziprasidone antagonizes dopamine D2 receptors, which reduces psychotic symptoms, and also blocks serotonin 5-HT2A receptors, which may improve mood and reduce extrapyramidal side effects. The intravenous formulation allows rapid onset of action for acute agitation or psychotic episodes in hospitalized patients.","oneSentence":"Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:44.198Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute agitation associated with schizophrenia"},{"name":"Acute agitation associated with bipolar disorder"}]},"trialDetails":[{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT00579670","phase":"","title":"Treatment of Schizophrenic Patients With Ziprasidone","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT00723606","phase":"PHASE3","title":"A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-09","conditions":"Schizophrenia","enrollment":376},{"nctId":"NCT00910988","phase":"NA","title":"Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-02","conditions":"Hyperglycemia, Hyperlipidemia","enrollment":46},{"nctId":"NCT00330863","phase":"PHASE4","title":"Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2006-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":357},{"nctId":"NCT03211897","phase":"","title":"Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation","status":"COMPLETED","sponsor":"Hennepin Healthcare Research Institute","startDate":"2017-06-15","conditions":"Agitation,Psychomotor","enrollment":737},{"nctId":"NCT02935998","phase":"PHASE4","title":"The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation","status":"UNKNOWN","sponsor":"Yang Fude","startDate":"2016-10","conditions":"Schizophrenia","enrollment":1000},{"nctId":"NCT00044655","phase":"PHASE4","title":"Switching Medication to Treat Schizophrenia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2001-07","conditions":"Schizophrenia","enrollment":219},{"nctId":"NCT00177164","phase":"PHASE3","title":"Risperdal Consta for Bipolar Disorder","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-11","conditions":"Bipolar I Disorder","enrollment":50},{"nctId":"NCT02282085","phase":"PHASE4","title":"Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia","status":"UNKNOWN","sponsor":"Matt Byerly","startDate":"2014-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT01198353","phase":"PHASE4","title":"Effectiveness of Ziprasidone for Patients With Schizophrenia","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2010-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":67},{"nctId":"NCT01485692","phase":"NA","title":"Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-02","conditions":"Psychomotor Agitation","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zeldox, Geodon","Geodon, Zeldox"],"phase":"marketed","status":"active","brandName":"Ziprasidone Injection","genericName":"Ziprasidone Injection","companyName":"Hennepin Healthcare Research Institute","companyId":"hennepin-healthcare-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Acute agitation associated with schizophrenia, Acute agitation associated with bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}